Cargando…
Immunotherapy Updates in Advanced Hepatocellular Carcinoma
SIMPLE SUMMARY: Advanced hepatocellular carcinoma (HCC) carries a grim prognosis, which has historically been compounded by a lack of available systemic therapies. Sorafenib monotherapy was the standard of care for front-line treatment of advanced HCC for many years, despite both poor tolerability a...
Autores principales: | Singh, Amisha, Beechinor, Ryan J., Huynh, Jasmine C., Li, Daneng, Dayyani, Farshid, Valerin, Jennifer B., Hendifar, Andrew, Gong, Jun, Cho, May |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8125389/ https://www.ncbi.nlm.nih.gov/pubmed/33946408 http://dx.doi.org/10.3390/cancers13092164 |
Ejemplares similares
-
Molecular Targets, Pathways, and Therapeutic Implications for Hepatocellular Carcinoma
por: Gong, Jun, et al.
Publicado: (2020) -
BRCA-Mutated Pancreatic Cancer: From Discovery to Novel Treatment Paradigms
por: Devico Marciano, Naomie, et al.
Publicado: (2022) -
Targeting the Fibroblast Growth Factor Receptor (FGFR) in Advanced Cholangiocarcinoma: Clinical Trial Progress and Future Considerations
por: Lee, Patrick C., et al.
Publicado: (2021) -
Current Treatment Landscape for Advanced Hepatocellular Carcinoma: Patient Outcomes and the Impact on Quality of Life
por: Li, Daneng, et al.
Publicado: (2019) -
Recent Advances in Targeted Therapies for Advanced Gastrointestinal Malignancies
por: C. Huynh, Jasmine, et al.
Publicado: (2020)